<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322543</url>
  </required_header>
  <id_info>
    <org_study_id>RAPID (Genesis) Registry CP-02</org_study_id>
    <nct_id>NCT00322543</nct_id>
  </id_info>
  <brief_title>Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)</brief_title>
  <official_title>Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conor Medsystems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™
      pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo
      lesions of the native coronary arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The registry is designed to evaluate 6-month in-stent late lumen loss in patients receiving
      the Corio™ drug-eluting stent.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic endpoint of in-stent late lumen loss at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) defined as an adjudicated composite of clinically driven target vessel revascularization, new myocardial infarction (MI) or cardiac death at 30 days, 6 months, 12 months and 2 years;</measure>
    <time_frame>30 days, 6 months, 12 months and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device, Lesion and Procedural Success; Coronary angiography at 6 months; IVUS measurements in IVUS cohort at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corio™ Pimecrolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Corio™ Pimecrolimus-eluting stent</intervention_name>
    <arm_group_label>Drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          1. Eligible for percutaneous coronary intervention (PCI).

          2. Documented stable or unstable angina pectoris

          3. Left ventricular ejection fraction (LVEF) ≥25%

          4. Acceptable candidate for coronary artery bypass graft surgery (CABG).

          5. Target Lesion &lt; 25 mm in length with RVD of 2.5 to 3.5 mm with visually estimated
             stenosis of &gt;= 50 and &lt; 100 %.

        Exclusion Criteria:

        General Exclusion Criteria

          1. Known sensitivity to pimecrolimus, the polymer (PLGA) or cobalt chromium.

          2. Planned treatment with any other PCI device in the target vessel(s).

          3. MI within 72 hours prior to the index procedure

          4. The patient is in cardiogenic shock.

          5. Cerebrovascular Accident (CVA) within the past 6 months.

          6. Acute or chronic renal dysfunction

          7. Contraindication to ASA or to clopidogrel.

          8. Thrombocytopenia

          9. Active gastrointestinal (GI) bleeding within the past 3 months.

         10. Any prior true anaphylactiod reaction to contrast agents

         11. Patient is currently taking chronic systemic steroid therapy or systemic
             immunosuppressant therapy or topical pimecrolimus.

         12. Female of childbearing potential.

         13. Life expectancy of less than 24 months due to other medical conditions.

         14. Co-morbid condition(s)

         15. Currently participating in another investigational drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Dante Pazzanese of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute Dante Pazzanese of Cardiology</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Abizaid, MD</name_title>
    <organization>Institute Dante Pazzanese of Cardiology</organization>
  </responsible_party>
  <keyword>Percutaneous coronary intervention (PCI)</keyword>
  <keyword>Drug eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

